ScoreWhy is Gland Pharma Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
Poor long term growth as Operating profit has grown by an annual rate -1.16% of over the last 5 years
3
Positive results in Dec 25
- NET SALES(Q) Highest at Rs 1,695.36 cr
- PBDIT(Q) Highest at Rs 434.88 cr.
- PBT LESS OI(Q) Highest at Rs 323.31 cr.
4
With ROE of 8.3, it has a Very Expensive valuation with a 3.3 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 24.91%, its profits have risen by 22.8% ; the PEG ratio of the company is 1.6
5
High Institutional Holdings at 40.56%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
6
Market Beating Performance
- The stock has generated a return of 24.91% in the last 1 year, much higher than market (BSE500) returns of 9.12%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Gland Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Gland Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Gland Pharma
25.22%
0.98
25.70%
Sensex
8.49%
0.74
11.41%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
13.75%
EBIT Growth (5y)
-1.16%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.14
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.57
Tax Ratio
32.07%
Dividend Payout Ratio
42.65%
Pledged Shares
0
Institutional Holding
40.56%
ROCE (avg)
22.73%
ROE (avg)
11.08%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
32
Price to Book Value
3.26
EV to EBIT
27.30
EV to EBITDA
19.64
EV to Capital Employed
4.02
EV to Sales
4.70
PEG Ratio
1.58
Dividend Yield
0.95%
ROCE (Latest)
13.82%
ROE (Latest)
8.27%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
NET SALES(Q)
Highest at Rs 1,695.36 cr
PBDIT(Q)
Highest at Rs 434.88 cr.
PBT LESS OI(Q)
Highest at Rs 323.31 cr.
PAT(Q)
Highest at Rs 279.06 cr.
EPS(Q)
Highest at Rs 15.87
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Gland Pharma
Profit After Tax (PAT) - Quarterly
At Rs 279.06 cr has Grown at 41.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 197.60 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 1,695.36 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 434.88 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 323.31 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 323.31 cr has Grown at 37.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 235.02 CrMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 279.06 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 15.87
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
